Biotronik bids for slice of DES (drug-eluting stent) market
This article was originally published in Clinica
Executive Summary
Biotronik has made a play for a stake in the potentially lucrative drug-eluting stent (DES) market for treating coronary artery disease by securing the exclusive rights to a new DES technology from fellow German firm Aachen Resonance.